Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro's life span depends on which question you're asking. Each pre-filled KwikPen contains four weekly doses and is licensed to stay in use for up to a defined period once opened; the medicine itself has a manufacturer shelf life before that. And then there's the bigger question — how long a course of treatment actually runs. These are three separate things, and it's worth understanding all three before you start. As a prescription-only medicine, Mounjaro (tirzepatide) is only available following a clinical assessment by a qualified prescriber, who will also guide you on how long your treatment should continue and when to review progress.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Every Mounjaro KwikPen carries an expiry date printed on the outer carton and on the pen itself. This shelf life is set by Eli Lilly, the manufacturer, and reflects the period during which the medicine has been shown to remain stable and effective under correct storage conditions. Correct storage means refrigeration between 2°C and 8°C, the kind of temperature found in the main compartment of a domestic fridge, not the door shelf or the freezer drawer.
The specific shelf life printed on your pen is the authoritative figure, and you should never use a pen past it. If your pen has been stored outside the fridge for any period, the calculation changes, because there is a limited room-temperature window before the medicine degrades. That exact window (the number of days allowed at room temperature, and the maximum temperature allowed) is set out in the Mounjaro Patient Information Leaflet and the Mounjaro SmPC on the eMC. The figure is not one we quote here, because it can be misapplied without the surrounding context; your prescriber or our pharmacy team can clarify it for your specific situation. One practical note: if your pen arrives during a hot week and you're not in to receive it, checking the storage conditions it travelled in matters, and our guide to tirzepatide lifespan covers how those conditions affect the medicine across its full shelf life.
Never use a pen that looks cloudy, contains visible particles, or has been frozen. These are signs the medicine may have degraded regardless of the date on the label.
Each Mounjaro KwikPen is designed to deliver four weekly injections. One pen, therefore, covers a single four-week treatment month. The pen is not a single-shot device, you use it once a week, then store it again between doses. After the first use, the in-use storage period begins, and the Patient Information Leaflet specifies how many days the opened pen may be kept before it must be discarded, regardless of how many doses remain.
This in-use window exists because once the seal on a drug product is broken, stability can no longer be guaranteed for the full original shelf life. Again, the exact figure lives in the leaflet rather than here, because applying it correctly requires reading the surrounding instructions. Our frequently asked questions page covers some common storage queries, and our prescribers are available for aftercare questions seven days a week.
Practical habits that help: keep the cap on between uses, store the pen upright in the fridge once opened (away from the back wall where temperatures can dip below 2°C), and never share your pen with anyone else. Needles should be removed after each injection and replaced with a fresh one before the next, both for hygiene and to maintain the pen mechanism's integrity.
This is the question most people are really asking. The clinical trials that led to Mounjaro's UK approval (principally the SURMOUNT programme) ran for 72 weeks, during which participants continued to lose weight across the full period rather than plateauing sharply early. That evidence base informed the UK licensing and the NICE recommendation for tirzepatide (TA1026), which advises that treatment should be reviewed at six months: if a person has not achieved at least 5% weight loss at their highest tolerated dose by that point, continuing on the medicine is assessed carefully. For people who are responding well, treatment can continue beyond six months under ongoing clinical oversight.
There is no fixed maximum duration stamped on the licence in the way Wegovy's NICE guidance specifies a two-year cap for NHS use. Whether Mounjaro becomes a long-term treatment (something our dedicated page on taking Mounjaro long-term explores in detail) depends on individual circumstances, the person's health goals, and their prescriber's ongoing assessment. Weight is influenced by biology in ways that don't simply switch off when a course ends; the question of what happens if you stop, and how to plan for that, is one our clinical team discusses with every patient approaching a review point, and our page on life after Mounjaro explores what that transition can look like in practice.
For an overview of tirzepatide's broader clinical profile and what to expect across a course of treatment, the NHS tirzepatide medicine page is a reliable starting point. And if you're thinking about the costs involved in maintaining treatment over time, our guide to Mounjaro costs in the UK explains what a legitimate private prescription actually includes.
Beyond the printed date, several practical factors influence whether a pen delivers a full, effective dose. Temperature excursions are the main one, a pen left in a car on a July afternoon, or posted through a letterbox into direct sun, may have been exposed to temperatures that degrade the active molecule even if the date on the label hasn't been reached. This is one reason the tirzepatide overview we've put together emphasises sourcing from a pharmacy with a verified, temperature-controlled supply chain.
Physical damage also matters. A KwikPen that has been dropped hard or stored with a bent needle tip may not inject correctly, which affects both the dose delivered and the injection-site experience. If anything about the pen looks wrong, don't use it and contact your pharmacy, and if you want to understand more about how the device itself is designed to work, our page on the Mounjaro bauble explains the pen's construction in straightforward terms.
Finally, the medicine's effectiveness over the life of your treatment is shaped by your prescriber's titration decisions. The starting dose of 2.5mg is a tolerability phase, it gives your system time to adjust before the dose moves up. Each subsequent increase happens at the prescriber's discretion based on your response and tolerance. If you have questions about where you are in that process, that conversation belongs with your prescriber rather than with the pen's label. At nume, a real clinician reads your consultation and progress notes, not an automated system, and our aftercare team is reachable all week. You can start your free consultation if you're ready to explore whether Mounjaro is appropriate for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.